• Users Online: 195
  • Print this page
  • Email this page
Year : 2021  |  Volume : 4  |  Issue : 2  |  Page : 43-51

In vitro maturation (IVM) procedure in oncofertility patients: A systemic review

1 Department of Obstetrics & Gynaecology, Faculty of Medicine, National University of Malaysia, Kuala Lumpur Campus, Cheras, Malaysia
2 Department of Obstetrics & Gynaecology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

Correspondence Address:
Prof. Nao Suzuki
Department of Obstetrics & Gynaecology, St Marianna University School of Medicine, Chrome-16-1 Sugao, Miyamae Ward, Kawasaki 216-8511
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tofj.tofj_1_22

Rights and Permissions

Our review aims to evaluate the benefit of in vitro maturation (IVM) in a standard control ovarian stimulation among oncofertility patients. A thorough search for relevant studies was conducted via PubMed, Google Scholar, Scopus, Cochrane Library, and clinical.gov databases. Our primary outcome was the oocyte maturation rate (OMR), which measures the number of immature oocytes that progress to mature (MII) oocytes following IVM. Our secondary outcomes were the number of oocytes and embryo cryopreservation following IVM for future use. The initial search identified 150 studies. Eight studies were included in our review after duplication assessment, title and abstract screening, and subsequent complete text evaluation tailored to our inclusion criteria. A total of 1040 patients with cancer with a mean age of 32.68 years were included in our review, in which half of them were diagnosed with breast cancer (BC). Most of the cycles were unstimulated. Two studies compared IVM in either follicular or luteal phases, and one study compared the in vitro fertilization (IVF) cycle with or without IVM. Our review included 7711 oocytes with 4604 oocytes that progressed to MII, obtaining an overall OMR of 59.70%. Following IVM, 335 embryos and 2380 oocytes were cryopreserved for future use. The oocyte numbers and maturation were comparable among all the studies, except that prognostic and predictor BC affects the IVM outcome. Our review concluded that IVM improves the number of MII following IVF cycles with similar survival rates, meiotic resumption rates, and blastocyst formation upon fertilization. Thus, IVM is a beneficial strategy for oncofertility patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded59    
    Comments [Add]    

Recommend this journal